Interim report, foreign filer
Open the filing on sec.gov
Biodexa Pharmaceuticals plc American Depositary Shs (BDRX)
Nasdaq: BDRX · Pharmaceutical Preparations · Cardiff · filing with the SEC since 2015
The companyfiscal 2023, as filed
Revenue£381,000-45.5%
Net income-£7.1M+7.5%
Earnings per share£-0.02+98.7%
Operating cash flow-£6.8M+3.1%
Cash£6.0M+110.5%
Debt£169,000+5.0%
Shareholders’ equity£4.7M+47.9%
Shares, diluted315.8M+6291.4%
Return on equity-56.0%
The recordfrom its filings
Filings in 2026100
Newest filingNov 9 · 6-K
Annual reportMar 27, 2026
Quarterly reportn/a
Next report due20-F by Apr 30
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents grantedn/a
Filer categoryNon-accelerated filer
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in GBP. Nothing here is a forecast.
News
Shelf offering
Open the filing on sec.gov
Shelf offering
Open the filing on sec.gov
Shelf offering
Open the filing on sec.gov
Shelf offering
Open the filing on sec.gov
Shelf offering
Open the filing on sec.gov
Shelf offering
Open the filing on sec.gov
Shelf offering
Open the filing on sec.gov
Shelf offering
Open the filing on sec.gov
Interim report, foreign filer
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.